|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Allergan_Neuroscience
gptkb:David_M._Pyott
gptkb:Allergan_Foundation
gptkb:Actavis
|
|
gptkbp:acquired
|
gptkb:Abb_Vie
|
|
gptkbp:acquisition
|
gptkb:Allergan_plc
gptkb:Zeltiq_Aesthetics
gptkb:Actavis
Aesthetics
Tobira Therapeutics
|
|
gptkbp:ceo
|
Brent Saunders
|
|
gptkbp:employees
|
approximately 18,000
|
|
gptkbp:focus
|
gptkb:hospital
cardiology
endocrinology
neurology
oncology
pediatrics
rare diseases
autoimmune diseases
chronic pain
hematology
neuroscience
orthopedics
psychiatry
dermatology
infectious diseases
immunology
radiology
pain management
women's health
respiratory diseases
ophthalmology
geriatrics
plastic surgery
transplantation
urology
gastroenterology
anesthesiology
pulmonology
metabolic diseases
cardiovascular
medical aesthetics
|
|
gptkbp:founded
|
gptkb:1983
|
|
gptkbp:founder
|
gptkb:Dr._J._Michael_Bishop
|
|
gptkbp:headquarters
|
gptkb:United_States
gptkb:Irvine,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Allergan, Inc.
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:part_of
|
gptkb:Abb_Vie_Inc.
|
|
gptkbp:products
|
gptkb:Botox
gptkb:Juvederm
gptkb:Restasis
|
|
gptkbp:revenue
|
$16.1 billion (2019)
|
|
gptkbp:subsidiary
|
gptkb:Allergan_Medical
gptkb:Allergan_Aesthetics
|
|
gptkbp:symbol
|
gptkb:AGN
|
|
gptkbp:traded_on
|
gptkb:NYSE
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.allergan.com
|